RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has
commenced an underwritten public offering of shares of its common
stock. All of the shares are being offered by Sangamo. In addition,
Sangamo expects to grant the underwriters of the offering a 30-day
option to purchase additional shares of its common stock at the
public offering price, less the underwriting discounts and
commissions. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering will be completed, or as to the actual size or terms of
the offering.
Sangamo anticipates using the net proceeds from the offering for
working capital and other general corporate purposes, including
support for its own and its partnered gene therapy, genome editing,
cell therapy and gene regulation product candidates and research
programs, its manufacturing facilities and other business
development activities.
Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays
Capital Inc. are acting as joint book-running managers for the
offering.
A registration statement relating to the shares was previously
filed with and became effective by rule of the Securities and
Exchange Commission. The offering is being made solely by means of
a prospectus. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the
Securities and Exchange Commission and will be available on the
Securities and Exchange Commission's website located at
http://www.sec.gov. A copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering,
when available, may be obtained from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (631) 274-2806; or from Wells Fargo Securities, LLC,
Attention: Equity Syndicate Department, 375 Park Avenue,
New York, New York 10152, or by
telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com; or from Barclays Capital Inc., c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at (888) 603-5847, or by email at
barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic medicines with the potential
to transform patients' lives using gene therapy, ex-vivo
gene-edited cell therapy, in vivo genome editing, and gene
regulation.
Forward Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to Sangamo's expectations
regarding the completion of the public offering, its expectations
with respect to granting the underwriters a 30-day option to
purchase additional shares and its anticipated use of net proceeds
from the offering. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, risks and
uncertainties related to completion of the public offering on the
anticipated terms or at all, market conditions and the satisfaction
of customary closing conditions related to the public offering.
These and other risks and uncertainties are described more fully in
the section captioned "Risk Factors" in the preliminary prospectus
supplement related to the public offering to be filed with the
Securities and Exchange Commission as well as Sangamo's Annual
Report on Form 10-K for the year ended December 31, 2018 filed with the Securities
and Exchange Commission on March 1,
2019 and other filings. Forward-looking statements contained
in this announcement are made as of this date, and Sangamo
undertakes no duty to update such information except as required
under applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-proposed-public-offering-of-common-stock-300824237.html
SOURCE Sangamo Therapeutics, Inc.